Our vision and commitment:

Leverage interdisciplinary science and engineering, computational biology and deep-learning to produce outcomes that fight disease and cultivate well-being.

Ultimately contribute towards improving the quality of life.

Deep-Biotech: an umbrella that hosts our mission tracks

Explore new territories. R&D towards new applied research. Develop new products and outcomes to provide services to industries and end users. 

Screenshot 2021-06-16 at 17.24.45



Explore and develop new interdisciplinary R&D concepts, tied to applied use cases, covering market needs and gaps. Build new partnerships, consortiums, novel MVPs, products and services via Tracks 2, 3. Exploit outcomes in business development opportunities.

Read more

Screenshot 2021-06-16 at 17.26.06

R&D, Products


Basic and applied research development towards novel MVPs/PoC, products within state-of-the art science and technology in computational biology and deep-learning.

Outcomes: "DeNViS", Deep Neural Virtual Screening for drug discovery.

Read more

Screenshot 2021-06-16 at 17.26.12

Services, R&D Consulting


Develop and deliver software engineering, production-level outcomes, publications, customised studies, tailor built solutions and consulting services to pharmaceutical, biotech-like industries.

More information soon.

Pipeline: Explore, R&D, Business Exploitation


How and Why

Screenshot 2021-06-16 at 17.14.40


Apply advanced deep-learning approaches at the intersection of computational biology, bio/chemo-informatics. Design and build end-to-end pipelines to develop usable services and products. 


Screenshot 2021-06-16 at 17.28.16


Have core health impact with applications e.g. in drug discovery and repurposing, single-cell multi-omics; aim to contribute in therapeutics, diagnostics; offer clinical insights in disease and wellness. 

Timeline and News

  • Mar 1, 2020

    First concept

    High-level motivation and brainstorming led to the initial drug discovery concept; after research we decided to focus on high-throughput virtual screening via structure-based protein-ligand affinity prediction.

  • May 1, 2020

    R&D Self-funded Project

    Form ML-Team; +new bio-engineer hiring; ongoing R&D work; production-level engineering scale up. 

  • Jul 20, 2020

    JEDI Grand Challenge submission

    Successful fast screening of 1B molecules; submission of ranked compounds to the JEDI Grand challenge international effort against covid-19 related proteins.

  • Oct 1, 2020

    R&D, Networking

    • Virtual screening R&D cont'd
    • Initiate single cell multi-omics tracks
    • Develop research project proposals and networking with pharma/biotech companies.
  • Jan 5, 2021


    • Bio-Explore concept and framework formation [Dec., 2021].
    • New bioinformaticians/bio-explore team [Jan., 2021].
    • Project kick-off [Feb., 2021].
  • Mar 1, 2021

    Positive Outcomes, +Business

    • JEDI positive feedback: deeplab is within 20-top finalists; molecules are to be screened in wet lab.
    • New strategic health market and business lead position.
  • May 1, 2021

    Upcoming potential

    • Submit Virtual screening product (DeNViS) business proposals on open funding calls (EIT, Bio-Tools) [May, 2021].
    • Technical report on Virtual Screening manuscript ready for publication.
    • Single-cell multi-omics 2nd cycle proposals with pharma industry [May, 2021].
    • Website goes live [Jun., 2021].

Express your interest

Open call for:

Partnerships. Experts. Customers. Investors.